Direkt zum Inhalt
Merck
  • Downregulation of L-type Ca2+ channel in rat mesenteric arteries leads to loss of smooth muscle contractile phenotype and inward hypertrophic remodeling.

Downregulation of L-type Ca2+ channel in rat mesenteric arteries leads to loss of smooth muscle contractile phenotype and inward hypertrophic remodeling.

American journal of physiology. Heart and circulatory physiology (2014-02-25)
Olga Kudryavtseva, Kate Møller Herum, Vibeke Secher Dam, Marthe Simonsen Straarup, Dmitry Kamaev, Donna M Briggs Boedtkjer, Vladimir V Matchkov, Christian Aalkjær
ZUSAMMENFASSUNG

L-type Ca(2+) channels (LTCCs) are important for vascular smooth muscle cell (VSMC) contraction, as well as VSMC differentiation, as indicated by loss of LTCCs during VSMC dedifferentiation. However, it is not clear whether loss of LTCCs is a primary event underlying phenotypic modulation or whether loss of LTCCs has significance for vascular structure. We used small interference RNA (siRNA) transfection in vivo to investigate the role of LTCCs in VSMC phenotypic expression and structure of rat mesenteric arteries. siRNA reduced LTCC mRNA and protein expression in rat mesenteric arteries 3 days after siRNA transfection to 12.7 ± 0.7% and 47.3 ± 13%, respectively: this was associated with an increased resting intracellular Ca(2+) concentration ([Ca(2+)]i). Despite the high [Ca(2+)]i, the contractility was reduced (tension development to norepinephrine was 3.5 ± 0.2 N/m and 0.8 ± 0.2 N/m for sham-transfected and downregulated arteries respectively; P < 0.05). Expression of contractile phenotype marker genes was reduced in arteries downregulated for LTCCs. Phenotypic changes were associated with a 45% increase in number of VSMCs and a consequent increase of media thickness and media area. Ten days after siRNA transfection arterial structure was again normalized. The contractile responses of LTCC-siRNA transfected arteries were elevated in comparison with matched controls 10 days after transfection. The study provides strong evidence for causal relationships between LTCC expression and VSMC contractile phenotype, as well as novel data addressing the complex relationship between VSMC contractility, phenotype, and vascular structure. These findings are relevant for understanding diseases, associated with phenotype changes of VSMC and vascular remodeling, such as atherosclerosis and hypertension.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Natriumchlorid, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Natriumchlorid -Lösung, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Natriumchlorid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
SAFC
Natriumchlorid -Lösung, 5 M
Sigma-Aldrich
Natriumchlorid -Lösung, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Natriumchlorid, 99.999% trace metals basis
Sigma-Aldrich
Natriumchlorid, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Natriumchlorid, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Natriumchlorid, BioPerformance Certified, ≥99% (titration), suitable for insect cell culture, suitable for plant cell culture
Sigma-Aldrich
Natriumchlorid, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Natriumchlorid-35Cl, 99 atom % 35Cl
Sigma-Aldrich
Natriumchlorid, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M
Sigma-Aldrich
Natriumchlorid, random crystals, optical grade, 99.9% trace metals basis
Sigma-Aldrich
Natriumchlorid -Lösung, 0.85%
Supelco
Natriumchlorid, reference material for titrimetry, certified by BAM, >99.5%
Supelco
Natriumchlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Natriumchlorid, tablet
Sigma-Aldrich
Natriumchlorid, tested according to Ph. Eur.
Sigma-Aldrich
MISSION® esiRNA, targeting human GNE
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Gne